Scienture Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SCNX in the last 30 days.
See all $SCNX insider activity →Scienture Holdings (SCNX) reported preliminary Q3 2026 revenue of $1.22M, up 256% sequentially, driven by Arbli and REZENOPY sales. The company aims for profitability in 2027.
Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additi
Scienture Holdings (SCNX) reported Q3 revenue of $1.22M, up 256% from last quarter, driven by sales of Arbli and Rezenopy. The company aims for 2027 profitability, with plans to expand distribution and market penetration. SCNX shares rose 2.08% in premarket trading.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SCNX (Scienture Holdings, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent SCNX coverage spans earnings, corporate actions and financial news.
Revenue surge may boost short‑term sentiment but scale is modest; price impact likely limited.
Positive revenue surprise and product launches suggest upward price pressure.
Revenue surge and new product launch suggest near‑term sales momentum and potential upside.
The reverse split should improve share price perception and maintain Nasdaq listing, but may cause short‑term volatility.
Positive commercial development expanding institutional access.
AlphAI scores every news story that mentions SCNX with an AI model for sentiment and relevance, and aggregates insider trades from Scienture Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Scienture Holdings (SCNX) reported preliminary Q3 2026 revenue of $1.22M, up 256% sequentially, driven by Arbli and REZENOPY sales. The company aims for profitability in 2027.
1 min readScienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additi
2 min readScienture Holdings (SCNX) reported Q3 revenue of $1.22M, up 256% from last quarter, driven by sales of Arbli and Rezenopy. The company aims for 2027 profitability, with plans to expand distribution and market penetration. SCNX shares rose 2.08% in premarket trading.
2 min readScienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Scienture Holdings, Inc. Announces Reverse Stock Split COMMACK, NY, September 30, 2026 (GLOBE NEWSWIRE) – SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhance
1 min readScienture Holdings (SCNX) announced that its Arbli™ (losartan potassium) Oral Suspension has been added to the formularies of three leading U.S. pediatric medical centers. Arbli™ addresses a $219 million U.S. losartan market, with 72 million prescriptions annually. The company reported increasing wholesale orders and sees significant growth potential, especially in pediatric care.
2 min readScienture Holdings, Inc. (NASDAQ: SCNX) announced a 1-for-25 reverse stock split, effective October 5, 2026. The company aims to meet Nasdaq's minimum bid price requirement and free up shares for future issuance. Outstanding shares will reduce from 41,064,146 to approximately 1,642,565. The stock will continue trading under the symbol SCNX.
2 min readScienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat
2 min readScienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.
4 min readScienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.
5 min readScienture Holdings (NASDAQ:SCNX) shares rose about 21% pre-market to $0.4046 after the company said it completed manufacturing of commercial launch inventory for REZENOPY (naloxone HCl) 10 mg nasal spray. Shipments to U.S. wholesalers are expected later this month, with retail availability in August. SCNX closed Thursday at $0.33.
4 min read
